🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT04359394
Recruiting Observational

International Rare And Severe Psoriasis Expert Network

NCT04359394 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2021-09-22
Last updated
2024-05-09

Condition(s) studied

Pustular Psoriasis (PP)

Investigational drug(s) / intervention(s)

biological samplingPhenotypic descriptionPhotography

biological sampling: In order to investigate the level of molecular pathophysiology, blood and punch biopsies will be collected of each patient. In up to two relatives per patient, 30mL blood will be collected only once.

Phenotypic description: Phenotypic characterization of the patient's clinical features

Photography: All affected areas will be photographed at each visit with 2-dimensional standardized photography

Study summary

This registry is a prospective observational study in order to describe primarily the natural course of PP subtypes and to gain detailed information about their phenotype.

Eligibility

Sex
ALL
Min age
6 Months
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Written informed consent of the patient or legal proxy in the registry * Diagnosis of PP confirmed by a dermatologist in the participant. The type of PP can be any one of PPP, GPP/Acute Generalized Exanthematous Pustulosis (AGEP), ACH or a mixed phenotype, according to the judgment of the investigator * GPP: Primary, sterile, macroscopically visible epidermal pustules on non-acral Skin with or without systemic Inflammation; with or without plaque psoriasis; either relapsing (\>1 episode) or persistent (\>3 months) * PPP: Primary, persistent (\>3 months), sterile, macroscopically visible epidermal pustules on palms and/or soles with or without plaque psoriasis * ACH: Primary, persistent (\>3 months), sterile, macroscopically visible epidermal pustules affecting the nail apparatus with or without plaque psoriasis * At the timepoint of inclusion, the participant must have had active pustulation with either white, yellow or brown pustules within six month before baseline. Active postulation at baseline is not mandatory for inclusion. * Sufficient language skills (in the languages which the patient information and the consent form is available) for the informed consent to participate * Patients of all ancestries and skin pigment type can be included * Direct non-affected adult (\>18 years old) relatives of the participant (up to two, namely mother, father, sibling) with the purpose to provide DNA for family trio sequencing analysis. The patient is not excluded from the study if no relatives are included. Exclusion Criteria: * Any medical or psychological condition in the treating physician's opinion which may prevent the patient in registry participation for the next 5 years * Lack of informed consent for registry participation

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
Klinikum der Universität München München Germany Recruiting
Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS Rome Italy Recruiting
Universitário do Porto Porto Portugal Recruiting
National Skin Centre Singapore Singapore Recruiting
Dermatology, University Hospital Basel Basel Switzerland Recruiting
University Hospital Zürich Zurich Switzerland Recruiting
Akdeniz University School of Medicine; Department of Dermatology and Venereology Antalya Turkey (Türkiye) Recruiting
Trakya University, Faculty of Medicine; Department of Dermatology and Venereology Edirne Turkey (Türkiye) Recruiting

More University Hospital, Basel, Switzerland trials in Turkey

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04359394 on ClinicalTrials.gov ↗ ← All trials in Turkey